- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07935824
Melodies for Mums to Be: Community Group Singing Intervention for Pregnant Women With Antenatal Depressive Symptoms (M4M2B)
Melodies for Mums to Be: Community Group Singing Intervention for Pregnant Women With Antenatal Depressive Symptoms - A Clinical, Biological and Implementation Evaluation
Antenatal depression (AND) is a common mental health condition, affecting approximately 1 in 10 expectant mothers, yet many find it difficult to access the right kind of support. Feeling low during pregnancy can affect day-to-day wellbeing and is associated with difficulties in feeling connected to the unborn baby and to others around them. If left unsupported, AND can have wider consequences, including an increased risk of preterm birth, difficulties in the developing relationship between mother and baby, and effects on the child's development after birth.
Group singing may offer an accessible, non-clinical way to support mental health during pregnancy, providing a friendly, non-judgemental space in which to meet others and take part in a shared activity. This study builds on research from the Melodies for Mums programme, which showed that community group singing reduced symptoms of depression and improved the relationship between mothers and their babies after birth. This study aims to investigate whether a similar programme, Melodies for Mums to Be, delivered during pregnancy, can reduce symptoms of depression, improve mood and wellbeing, and support the relationship between expectant mothers and their unborn babies. The study is funded by the Psychiatry Research Trust and delivered by King's College London in partnership with Breathe Arts Health Research.
Fifty expectant mothers aged 18 or over who are experiencing symptoms of low mood (a score of 10 or above on the Edinburgh Postnatal Depression Scale) will be recruited from across London from 16 weeks' gestation. Participants will be randomly allocated either to attend a six-week group singing programme during pregnancy or to receive the same programme after the birth of their baby, ensuring that all participants have the opportunity to take part. Sessions will last approximately 60 minutes, be held weekly at community cultural venues across London, and be led by trained facilitators. No musical experience is needed.
Participants will complete questionnaires and interviews before, during, and after the programme, and at approximately 8 weeks, 7 months, and 12 months after giving birth. The main outcome is the change in depressive symptoms over the six-week programme period, compared between the two groups. Participants who consent will also provide saliva and blood samples to help understand whether singing during pregnancy is associated with changes in biological markers of stress and bonding.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Antenatal depression (AND) affects approximately 10-20% of pregnant women and represents a significant public health concern with implications for both maternal wellbeing and infant development. AND has been associated with adverse outcomes including increased risk of preterm birth, low birth weight, and altered infant stress regulation. Early identification and support for women experiencing depressive symptoms during pregnancy is therefore critical for both maternal and infant health.
One potential pathway linking depression during pregnancy to later developmental outcomes is maternal-foetal attachment, defined as the emotional bond a pregnant woman develops with her unborn baby. Lower levels of maternal-foetal attachment have been associated with greater severity of depressive symptoms during pregnancy. Singing interventions have been associated with improvements in mood, reductions in stress-related biomarkers such as cortisol, and enhanced feelings of social connection. However, many existing studies have been conducted in community samples where participants report relatively low levels of psychological distress at baseline, meaning limited evidence exists regarding the effectiveness of such interventions for women experiencing clinically meaningful depressive symptoms during pregnancy.
In the postnatal period, the SHAPER-PND Melodies for Mums (M4M) clinical trial demonstrated reductions in depressive symptoms and improvements in mother-infant interaction and maternal communication towards the infant. However, most existing research has focused on postnatal interventions, and relatively little work has explored whether similar approaches are beneficial when delivered during pregnancy, particularly among women experiencing antenatal depression. Building on the evidence generated through the SHAPER-PND trial, the present study aims to evaluate the effectiveness of adapting a community group singing intervention for delivery during pregnancy among women experiencing antenatal depressive symptoms.
Trial design and aims: The Melodies for Mums to Be (M4M2B) study will be conducted by King's College London in collaboration with Breathe Arts Health Research. The study will use a two-arm randomised delayed-access design, whereby all eligible participants will be offered the M4M2B intervention; the immediate access arm during pregnancy, and the delayed access arm postnatally following completion of the 8-week postpartum assessment. The intervention consists of six weekly group singing sessions delivered in community cultural venues across London, in groups of up to 15 participants. Eligibility screening will be offered from 16 weeks' gestation onwards, and the intervention will usually commence between 20+0 and 28+6 weeks of gestation. Participants will be assessed at six timepoints: baseline, midpoint (week 3-4), post-intervention (week 6-8), and approximately 8 weeks, 7 months, and 12 months postpartum. At baseline and post-intervention, participants will attend an in-person visit to the NIHR Clinical Research Facility at King's College Hospital for a video-recorded guided interaction task with the unborn baby (Prenatal Marschak Interaction Method; Prenatal MIM) and, for those who consent, blood and saliva sample collection. All other assessments will be routinely carried out online, either as a video call on Microsoft Teams for interviews or through online surveys via REDCap. Individual participants will be involved in the study from enrolment to their final 12-month postpartum follow-up.
The study will evaluate the clinical effectiveness of the intervention in reducing depressive symptoms and improving maternal-foetal attachment and interaction quality, as well as different aspects of maternal mental health including anxiety, perceived stress, and emotion regulation. The study will also evaluate the implementation effectiveness of the intervention, including its uptake, acceptability, appropriateness and feasibility.
Participants and Recruitment process: The study aims to recruit 50 pregnant women. Recruitment will be primarily carried out through: recruitment via SLaM, through signposting and awareness within relevant community services; social media and community outreach, including online groups, forums, and local community publicity, aimed at pregnant people and parents; publicity in healthcare settings, including posters and flyers displayed in GP practices and other relevant antenatal services or clinics; antenatal education and community spaces, including antenatal classes, Children and Family Centres, and local newsletters/mailing lists; and self-referral. Potential participants will be directed to a registration form on Breathe's website. When a place becomes available and the participant is within the relevant gestational window, they will be invited to complete the Edinburgh Postnatal Depression Scale (EPDS) online to assess depressive symptoms. Those scoring 10 or above will be considered eligible. Eligible participants will then be contacted by the KCL research team, provided with the full Participant Information Sheet, and given at least 24 hours to consider participation before completing the full informed consent process. Following completion of baseline assessments required for randomisation, participants will be randomised (1:1) in REDCap.
Measures and Procedures: Measures will be collected from study participants at six timepoints during the study.
- Baseline (within two weeks prior to the first M4M2B session): Demographic Questionnaire; Antenatal Risk Factor Questionnaire (ARFQ); Childhood Trauma Questionnaire (CTQ); Composite Abuse Scale Revised Short-Form (CASR-SF); Mini International Neuropsychiatric Interview (MINI); Edinburgh Postnatal Depression Scale (EPDS); Patient Health Questionnaire (PHQ-9); Generalised Anxiety Disorder Scale (GAD-7); Perceived Stress Scale (PSS); Difficulties in Emotion Regulation Scale (DERS-16); Maternal Antenatal Attachment Scale (MAAS); Body Understanding Measure for Pregnancy Scale (BUMPS); Multidimensional Scale of Perceived Social Support (MSPSS); Couple Satisfaction Index (CSI-16); Adult Attachment Questionnaire (AAQ); Prenatal MIM; blood and saliva samples.
- Midpoint (week 3-4): EPDS; PHQ-9; GAD-7; MAAS; BUMPS.
- Post-intervention (week 6-8): Repeated Demographic Questionnaire; EPDS; PHQ-9; GAD-7; PSS; DERS-16; MAAS; BUMPS; MSPSS; CSI-16; Prenatal MIM; blood and saliva samples.
- Postnatal Follow-up 1 (approximately 8 weeks postpartum): Repeated Demographic Questionnaire; Delivery Questionnaire; Brief Life Events Questionnaire (BLE); MINI; EPDS; PHQ-9; GAD-7; PSS; DERS-16; Maternal Postnatal Attachment Scale (MPAS); Parenting Stress Index Short Form (PSI-4); MSPSS; CSI-16; Mother-Infant Interaction Video (CARE-Index; PCAMS); maternal and infant saliva samples.
- Postnatal Follow-up 2 (approximately 7 months postpartum): EPDS; PHQ-9; GAD-7; PSS; MPAS; MSPSS.
- Postnatal Follow-up 3 (approximately 12 months postpartum): Repeated Demographic Questionnaire; BLE; MINI; EPDS; PHQ-9; GAD-7; PSS; DERS-16; MPAS; PSI-4; MSPSS; CSI-16; Mother-Infant Interaction Video (CARE-Index; PCAMS); maternal and infant saliva samples.
Implementation measures (Acceptability of Intervention Measure, AIM; Intervention Appropriateness Measure, IAM; Feasibility of Intervention Measure, FIM) will be collected during the intervention phase only, for the immediate access arm antenatally and for the delayed access arm postnatally, and from both arms at 12 months postpartum. Biological samples will be collected from participants who consent to biological sample collection. All recordings will be coded by trained coders using validated scales (Prenatal MIM; CARE-Index; PCAMS), blind to participant allocation where possible.
Collection, transportation and storage of samples: Diurnal saliva samples consisting of six samples will be collected by participants at home at awakening, at 15, 30, and 60 minutes post-awakening, at midday, and at 8pm, in relation to Session 1 and Session 6 of the singing programme, and at the 8-week and 12-month postpartum assessments. Infant saliva samples consisting of two samples will be collected by parents at home using SalivaBio Infant Swabs at the 8-week and 12-month postpartum assessments. Pre- and post-session saliva and passive drool samples will be collected on site immediately before and after Session 1 and Session 6. Blood samples will be collected by a trained phlebotomist at the NIHR Clinical Research Facility at King's College Hospital at baseline and post-intervention. Samples will be stored at the Maurice Wohl Clinical Neuroscience Institute, King's College London (diurnal samples at -20°C; pre-post session, passive drool and blood samples at -80°C) and used for cortisol, oxytocin, cytokines, and other stress-related biomarker and hormonal analyses. Results will be identified according to anonymised participant codes and stored securely.
Follow-up: Follow-up with all participants will be conducted at approximately 8 weeks, 7 months, and 12 months postpartum. Participants' wellbeing will be monitored through the questionnaires, and any concerns will be flagged to the designated safeguarding lead.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Katie Hazelgrove, PhD
- Numéro de téléphone: 020 7848 0726
- E-mail: melodies4mums2b@kcl.ac.uk
Sauvegarde des contacts de l'étude
- Nom: Seungyoung Aeron Kim, MSc
- E-mail: seungyoung.2.kim@kcl.ac.uk
Lieux d'étude
-
-
United Kingdom
-
London, United Kingdom, Royaume-Uni, SE5 9RT
- King's College London, Maurice Wohl Clinical Neuroscience Institute
-
Contact:
- Katie Hazelgrove, PhD
- Numéro de téléphone: 020 7848 0726
- E-mail: melodies4mums2b@kcl.ac.uk
-
Contact:
- Seungyoung Aeron Kim, MSc
- E-mail: seungyoung.2.kim@kcl.ac.uk
-
Chercheur principal:
- Carmine Pariante, MD, PhD, FRCPsych
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Pregnant women aged 18 years or older.
- ≥16 weeks' gestation at enrolment.
- ≤28+6 weeks' gestation at the scheduled start of the antenatal cohort.
- Score ≥10 on the Edinburgh Postnatal Depression Scale (EPDS) at screening, indicating antenatal depressive symptoms.
- Able to provide informed consent and participate in study procedures, including group sessions, facilitated in English
Exclusion Criteria:
- Participants unable to engage with study procedures (e.g., understand study information and give informed consent).
- Participants unable to attend in-person singing sessions due to geographic distance or travel limitations.
- Participants currently attending another structured singing or music-based activity during the study period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Immediate access
Participants randomised to the immediate access arm will receive immediate antenatal access to the six-week group singing intervention, offered alongside existing care. |
Melodies for Mums to Be (M4M2B) is a community-based group singing intervention delivered by Breathe Arts Health Research, based on the Melodies for Mums model. The intervention consists of six weekly group singing sessions delivered in community cultural venues across London, in groups of up to 15 participants. Sessions last approximately 60 minutes and are facilitated by trained Breathe artists with experience delivering perinatal singing interventions. Each session includes guided group singing, breathing and relaxation exercises, and opportunities for informal peer interaction. The repertoire is designed to be accessible regardless of musical experience and may include songs drawn from diverse cultural and musical traditions. Sessions are facilitated in English throughout.
Autres noms:
|
|
Autre: Delayed access
Participants randomised to the delayed access arm will not attend antenatal singing sessions and will receive usual care during pregnancy. They will complete the same antenatal assessment schedule as participants in the immediate access arm. The delayed access arm will be offered the same six-week singing intervention postnatally, commencing after completion of the 8-week postpartum assessment. |
Melodies for Mums to Be (M4M2B) is a community-based group singing intervention delivered by Breathe Arts Health Research, based on the Melodies for Mums model. The intervention consists of six weekly group singing sessions delivered in community cultural venues across London, in groups of up to 15 participants. Sessions last approximately 60 minutes and are facilitated by trained Breathe artists with experience delivering perinatal singing interventions. Each session includes guided group singing, breathing and relaxation exercises, and opportunities for informal peer interaction. The repertoire is designed to be accessible regardless of musical experience and may include songs drawn from diverse cultural and musical traditions. Sessions are facilitated in English throughout.
Autres noms:
Participants will receive usual care during pregnancy. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in depressive symptoms (Edinburgh Postnatal Depression Scale, EPDS)
Délai: From baseline (before the first session) to post-intervention (week 6 to 8)
|
The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report questionnaire developed to detect depression in the perinatal period, and is validated for use in pregnancy. For each statement, women choose one of four responses that best describes how they have felt over the past week. Each item is scored 0 to 3; total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms. |
From baseline (before the first session) to post-intervention (week 6 to 8)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in maternal-foetal attachment (Maternal Antenatal Attachment Scale, MAAS)
Délai: Baseline (before the first session), midpoint (week 3 to 4) and post-intervention (week 6 to 8)
|
The Maternal Antenatal Attachment Scale (MAAS) is a 19-item self-report questionnaire assessing a pregnant woman's thoughts and feelings towards her unborn baby, covering the quality of attachment and the intensity of preoccupation with the baby. Total scores range from 19 to 95, with higher scores indicating stronger maternal antenatal attachment. |
Baseline (before the first session), midpoint (week 3 to 4) and post-intervention (week 6 to 8)
|
|
Change in maternal-foetal interaction quality (Prenatal Marschak Interaction Method, Prenatal MIM)
Délai: Baseline (before the first session) and post-intervention (week 6 to 8)
|
The Prenatal Marschak Interaction Method (Prenatal MIM) is a 15-20 minute video-recorded observational assessment in which the mother completes a series of structured tasks directed at her unborn baby (e.g., talking to, touching and singing to the baby). Recordings are coded by trained coders using the Emotional Availability Pregnancy Screener (Emotional Availability Scales, 4th edition). Two dimensions are rated: Sensitivity (e.g., affect, responsiveness to the baby, bodily attunement, acceptance and amount of interaction) and Non-hostility (e.g., absence of negativity, disrespectful remarks or hostile themes). Each dimension is scored from 1 to 7, with higher scores indicating greater maternal sensitivity and lower hostility towards the unborn baby. |
Baseline (before the first session) and post-intervention (week 6 to 8)
|
|
Change in depressive symptoms (EPDS) across all study timepoints
Délai: Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report questionnaire measuring depressive symptoms. Each item is scored 0 to 3; total scores range from 0 to 30, with higher scores indicating more severe symptoms. Change is assessed across all study timepoints. |
Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
|
Change in depressive symptoms (Patient Health Questionnaire, PHQ-9)
Délai: Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report questionnaire based on the diagnostic criteria for major depression. Respondents rate how often they have been bothered by each symptom over the past two weeks, from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
|
Change in anxiety symptoms (Generalised Anxiety Disorder 7-Item, GAD-7)
Délai: Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
The Generalised Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self-report questionnaire measuring symptoms of generalised anxiety. Respondents rate how often they have been bothered by each symptom over the past two weeks, from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. |
Baseline (before the first session), midpoint (week 3 to 4), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
|
Change in perceived stress (Perceived Stress Scale, PSS)
Délai: Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
The Perceived Stress Scale (PSS) is a 10-item self-report questionnaire measuring the degree to which situations in one's life over the past month are appraised as unpredictable, uncontrollable and overloading. Each item is rated from 0 (never) to 4 (very often), with positively worded items reverse-scored. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. |
Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
|
Change in emotion regulation (Difficulties in Emotion Regulation Scale - Short Form 16, DERS-16)
Délai: Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks and 12 months postpartum
|
The Difficulties in Emotion Regulation Scale - Short Form (DERS-16) is a 16-item self-report questionnaire assessing difficulties in emotion regulation, including emotional clarity, acceptance of emotional responses, impulse control, goal-directed behaviour when distressed and access to effective regulation strategies. Each item is rated from 1 (almost never) to 5 (almost always). Total scores range from 16 to 80, with higher scores indicating greater difficulties in emotion regulation. |
Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks and 12 months postpartum
|
|
Change in body image during pregnancy (Body Understanding Measure for Pregnancy Scale, BUMPS)
Délai: Baseline (before the first session), midpoint (week 3 to 4) and post-intervention (week 6 to 8)
|
The Body Understanding Measure for Pregnancy Scale (BUMPS) is a 19-item self-report questionnaire measuring body image during pregnancy across three subscales: satisfaction with appearing pregnant, concerns about weight gain and the physical burden of pregnancy. Total scores range from 19 to 95, with higher scores indicating greater body dissatisfaction. |
Baseline (before the first session), midpoint (week 3 to 4) and post-intervention (week 6 to 8)
|
|
Change in perceived social support (Multidimensional Scale of Perceived Social Support, MSPSS)
Délai: Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
The Multidimensional Scale of Perceived Social Support (MSPSS) is a 12-item self-report questionnaire measuring perceived support from family, friends and a significant other. Each item is rated from 1 (very strongly disagree) to 7 (very strongly agree). Total scores range from 12 to 84, with higher scores indicating greater perceived social support. |
Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks, 7 months and 12 months postpartum
|
|
Acceptability of the intervention (Acceptability of Intervention Measure, AIM)
Délai: Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
The Acceptability of Intervention Measure (AIM) is a 4-item self-report implementation outcome measure assessing how acceptable participants find the intervention. Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the items, ranging from 1 to 5, with higher scores indicating greater acceptability. Collected during the intervention phase only (antenatally for the immediate access arm; postnatally for the delayed access arm), and from both arms at 12 months postpartum. |
Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
|
Appropriateness of the intervention (Intervention Appropriateness Measure, IAM)
Délai: Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
The Intervention Appropriateness Measure (IAM) is a 4-item self-report implementation outcome measure assessing how appropriate (fitting, suitable) participants find the intervention. Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the items, ranging from 1 to 5, with higher scores indicating greater appropriateness. Collected during the intervention phase only (antenatally for the immediate access arm; postnatally for the delayed access arm), and from both arms at 12 months postpartum. |
Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
|
Feasibility of the intervention (Feasibility of Intervention Measure, FIM)
Délai: Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
The Feasibility of Intervention Measure (FIM) is a 4-item self-report implementation outcome measure assessing how feasible (workable, possible to take part in) participants find the intervention. Each item is rated from 1 (completely disagree) to 5 (completely agree), and the score is the mean of the items, ranging from 1 to 5, with higher scores indicating greater feasibility. Collected during the intervention phase only (antenatally for the immediate access arm; postnatally for the delayed access arm), and from both arms at 12 months postpartum. |
Programme midpoint and end; approximately 8 weeks postpartum (immediate access arm only); approximately 12 months postpartum
|
|
Uptake/reach of the intervention
Délai: Throughout the recruitment period
|
Number of eligible participants who sign up to the intervention. |
Throughout the recruitment period
|
|
Intervention adherence and attrition
Délai: Weekly during the six-week intervention
|
Number of participants adhering to the intervention and drop-outs measured weekly. |
Weekly during the six-week intervention
|
|
Maternal diurnal salivary cortisol
Délai: Week 1 and week 6 of the intervention (around Session 1 and Session 6); approximately 8 weeks and 12 months postpartum
|
Maternal salivary cortisol concentration (nmol/L), measured by immunoassay in saliva samples collected at home using Salivettes at six points across one day: at awakening, 15, 30 and 60 minutes after awakening, at midday and at 8pm, to characterise the diurnal cortisol profile. Collected from participants who consent to biological sampling. |
Week 1 and week 6 of the intervention (around Session 1 and Session 6); approximately 8 weeks and 12 months postpartum
|
|
Infant diurnal salivary cortisol
Délai: Approximately 8 weeks and 12 months postpartum
|
Infant salivary cortisol concentration (nmol/L), measured by immunoassay in saliva samples collected at home by the mother using infant swabs at two points across one day: at awakening and at 8pm. Collected from infants of participants who consent to infant biological sampling. |
Approximately 8 weeks and 12 months postpartum
|
|
Pre-post session maternal salivary cortisol
Délai: Immediately before and immediately after Session 1 (week 1) and Session 6 (week 6) of the intervention
|
Maternal salivary cortisol concentration (nmol/L), measured by immunoassay in saliva samples (Salivette) collected on site immediately before and immediately after the singing session. Collected during the intervention phase only (antenatally for the immediate access arm; postnatally for the delayed access arm). |
Immediately before and immediately after Session 1 (week 1) and Session 6 (week 6) of the intervention
|
|
Pre-post session maternal salivary oxytocin
Délai: Immediately before and immediately after Session 1 (week 1) and Session 6 (week 6) of the intervention
|
Maternal salivary oxytocin concentration (pg/mL), measured by immunoassay in passive drool saliva samples collected on site immediately before and immediately after the singing session. Collected during the intervention phase only (antenatally for the immediate access arm; postnatally for the delayed access arm). |
Immediately before and immediately after Session 1 (week 1) and Session 6 (week 6) of the intervention
|
|
Postnatal maternal attachment (Maternal Postnatal Attachment Scale, MPAS)
Délai: Approximately 8 weeks, 7 months and 12 months postpartum
|
The Maternal Postnatal Attachment Scale (MPAS) is a 19-item self-report questionnaire assessing a mother's thoughts and feelings towards her infant, covering the quality of attachment, absence of hostility and pleasure in interaction. Total scores range from 19 to 95, with higher scores indicating stronger maternal attachment to the infant. |
Approximately 8 weeks, 7 months and 12 months postpartum
|
|
Mother-infant interaction quality (Crittenden Child-Adult Relationship Experimental Index, CARE-Index)
Délai: Approximately 8 weeks and 12 months postpartum
|
The Crittenden Child-Adult Relationship Experimental Index (CARE-Index) is a validated observational tool for assessing parent-infant interaction. A 3-minute video recording of the mother and baby in free play is coded by trained coders. The interaction is rated on scales of 0 to 14 for maternal behaviour (sensitivity, control and unresponsiveness), infant behaviour (cooperation, compulsivity, difficultness and passivity) and dyadic synchrony. Higher maternal sensitivity, infant cooperation and dyadic synchrony scores indicate more attuned interaction; higher maternal control and unresponsiveness, and higher infant compulsivity, difficultness and passivity scores indicate less attuned interaction. |
Approximately 8 weeks and 12 months postpartum
|
|
Maternal communication during mother-infant interaction (Parental Cognitive Attributions and Mentalization Scale, PCAMS)
Délai: Approximately 8 weeks and 12 months postpartum
|
The Parental Cognitive Attributions and Mentalization Scale (PCAMS) is a validated tool for assessing the quality of parental communication. Maternal speech during a 3-minute video recording of the mother and baby in free play is coded by trained coders, across three domains: mentalising comments (the mother's awareness and interpretation of her infant's cognitive, emotional and physiological states); attentional focus (infant-, parent- or other-focused speech); and affective connotation (positive or negative comments). Each category is reported as a proportion (0 to 100%) of maternal comments. Higher proportions of mentalising and infant-focused comments indicate more sensitive, supportive communication; higher proportions of negative or parent-focused comments indicate less sensitive communication. |
Approximately 8 weeks and 12 months postpartum
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in couple relationship satisfaction (Couple Satisfaction Index - Short Form, CSI-16)
Délai: Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks and 12 months postpartum
|
The Couple Satisfaction Index - Short Form (CSI-16) is a 16-item self-report questionnaire measuring satisfaction with a romantic relationship, including happiness, warmth and closeness in the relationship. Total scores range from 0 to 81, with higher scores indicating greater relationship satisfaction. |
Baseline (before the first session), post-intervention (week 6 to 8), and approximately 8 weeks and 12 months postpartum
|
|
Parenting stress (Parenting Stress Index, Fourth Edition Short Form, PSI-4-SF)
Délai: Approximately 8 weeks and 12 months postpartum
|
The Parenting Stress Index, Fourth Edition Short Form (PSI-4-SF) is a 36-item self-report questionnaire measuring stress within the parent-child system across three subscales: parental distress, parent-child dysfunctional interaction and difficult child. Each item is rated from 1 (strongly disagree) to 5 (strongly agree). Total stress scores range from 36 to 180, with higher scores indicating greater parenting stress. |
Approximately 8 weeks and 12 months postpartum
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Carmine Pariante, MD, PhD, FRCPsych, King's College London
Publications et liens utiles
Publications générales
- Rebecchini L, Bind RH, Estevao C, Hazelgrove K, Priestley K, Laijawala R, Sangha S, Sethna V, Woods AJ, Crane N, Manoharan M, Burton A, Dye H, Osborn T, Greenwood L, Fancourt D, Pariante CM, Dazzan P. Maternal communication and attachment following a group singing intervention for postnatal depression: findings from the SHAPER-PND trial. Psychol Med. 2026 Apr 7;56:e98. doi: 10.1017/S0033291726103997.
- Bind RH, Lawrence AJ, Estevao C, Hazelgrove K, Priestley K, Rebecchini L, Laijawala R, Miller C, Healey A, Agwuna J, Sevdalis N, Bakolis I, Davis R, Lopez MB, Woods AJ, Crane N, Manoharan M, Burton A, Dye H, Osborn T, Greenwood L, Perkins R, Dazzan P, Fancourt D, Pariante CM. Clinical effectiveness, implementation effectiveness and cost-effectiveness of a community singing intervention for postnatal depressive symptoms, SHAPER-PND: randomised controlled trial. Br J Psychiatry. 2025 Dec;227(6):836-845. doi: 10.1192/bjp.2025.10377. Epub 2025 Oct 15.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Dépression périnatale
- Sciences de la mise en œuvre
- Intervention musicale
- Interaction mère-enfant
- Santé mentale maternelle
- Dépression prénatale
- Santé mentale périnatale
- Lien mère-enfant
- Biomarqueurs de stress
- Depression in pregnancy
- Arts-based interventions
- Creative health
- Group singing
- Maternal-foetal attachment
- Maternal-fetal attachment
Autres numéros d'identification d'étude
- IRAS 371192
- 26/PR/0912 (Autre identifiant: Health Research Authority (HRA))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Anonymised data sets will be made available on the KCL Research Data Management System.
Protocol will be published in a peer-reviewed journal.
Délai de partage IPD
Following publication of the main study results.
Critères d'accès au partage IPD
Requests to access the anonymised data can be made to the research team, and access will be granted only for ethically approved research studies.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .